CN104042767A - Pharmaceutical composition for treating chronic pharyngitis as well as preparation method and application of pharmaceutical composition - Google Patents
Pharmaceutical composition for treating chronic pharyngitis as well as preparation method and application of pharmaceutical composition Download PDFInfo
- Publication number
- CN104042767A CN104042767A CN201410305488.9A CN201410305488A CN104042767A CN 104042767 A CN104042767 A CN 104042767A CN 201410305488 A CN201410305488 A CN 201410305488A CN 104042767 A CN104042767 A CN 104042767A
- Authority
- CN
- China
- Prior art keywords
- parts
- fructus
- pharmaceutical composition
- radix
- pharyngitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a pharmaceutical composition for treating chronic pharyngitis. Crude drugs of the pharmaceutical composition include the following drugs in parts by weight: 12-18 parts of myrobalan, 3-9 parts of phyllanthus emblica, 12-18 parts of dark plum, 3-9 parts of prunus mume, 7-13 parts of liquorice, 9-15 parts of radix platycodonis, 17-23 parts of radix scrophulariae, 5-11 parts of chrysanthemum, 12-18 parts of momordica grosvenori and 5-11 parts of sterculia lychnophora. The pharmaceutical composition provided by the invention can be used for effectively treating chronic pharyngitis, has the effect of eliminating or relieving symptoms such as pharyngeal discomfort, foreign body sensation, gargalesthesia, burning heat sensation, dry sensation or irritation sensation caused by pharyngitis, hypodynia, cough, associated nausea, pharyngeal mucous membrane thickening, sticky or purulent secretions and is high in total curative effective rate.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of chronic pharyngitis and its production and use.
Background technology
Chronic pharyngitis is commonly encountered diseases, the frequently-occurring disease of hals,Nasen und Ohrenheilkunde, and clinical symptoms is various, as pharyngeal sense of discomfort, foreign body sensation, burning sensation, dry sensation, gargalesthesia and hypodynia sense etc.Chronic pharyngitis is the pharyngeal pathological changes of diffusivity that chronic infection causes, pathological characters is mainly pharynx mucous layer chronic congestion, and its blood vessel has infiltration of more lymphocytes around, connective tissue and lymphadenosis under mucosa, severe one forms pharynx rear wall graininess protuberance, mucous gland hypertrophy, hypersecretion.Cardinal symptom is pharyngeal discomfort, as foreign body sensation, dry pharynx, itching throat, pharynx twinge, and cough, the even vomiting of feeling sick.The cause of disease comprises: 1. local factor: acute pharyngitis shows effect repeatedly, can transfer to chronic.Adjacent organs disease, as the rheuminess logistics such as chronic tonsillitis, apicitis, dental caries, chronic rhinitis, chronic sinusitis enter pharyngeal, or chronic cacorhinia causes nose dysventilation and with mouth breathing, and pharyngeal long-term irriate as tobacco and wine excessively, stimulation and the maror etc. of dust, harmful gas can cause primary disease.2. systemic factor: as anemia, dyspepsia, lower respiratory tract chronic inflammatory disease, cardiovascular disease, endocrine dysfunction, vitamin deficiency and immunologic hypofunction etc.
In chronic pharyngitis, concrete classification comprises chronic simple pharyngitis and chronic hypertrophic pharyngitis.Chronic simple pharyngitis, pathological changes, mainly at mucous layer, shows as pharyngeal mucosa chronic congestion, and its blood vessel has infiltration of more lymphocytes around, also visible leukocyte and plasmocyte infiltrating.Connective tissue proliferation under mucosa and mucosa.Mucous gland can be loose, and secretory function is hyperfunction, mucus secretion increasing.Common adult, the course of disease is long, easily recurrence.Chronic hypertrophic pharyngitis, normal is the secondary disease of chronic simple pharyngitis, its pharyngeal mucosa hyperemia thickens, under mucosa and mucosa, there are connective tissue and lymphadenosis more widely, lymphadenosis projection around mucous gland, on pharynx rear wall, cash as multiple granule protuberances, be chronic congestion shape, be sometimes even fused into a slice.Inflammatory exudate in mucous gland is closed wherein, forms cryptomere white point, visible yellow-white exudate when ulceration at the top of lymph granule protuberance.This kind of pharyngitis is often involved lateral pharyngeal band lymphoid tissue, makes its hypertrophy plumpness, is streak.
Chronic pharyngitis is taken antibiosis and is have certain therapeutical effect, but due to the easily outbreak repeatedly of this sickly complexion, some courses of disease are longer, if long-term taking antibiotic can cause bacterial resistance, and the multiple complications such as the interior normal flora imbalance of body.Exploitation Chinese medicine preparation treatment chronic pharyngitis is rational selection.Peng Shunlin etc., think that by clinical observation the pathogenic characteristic of chronic pharyngitis should be " deficiency of YIN and the qi depression to blood stasis forming on deficiency of YIN basis; treatment is when also using with YIN nourishing sore-throat relieving and promoting flow of QI and blood ", and disclose a kind of prescription for the treatment of chronic pharyngitis: Radix Ophiopogonis, Radix Salviae Miltiorrhizae, Radix Paeoniae Rubra, Rhizoma Chuanxiong, Radix Scrophulariae, Fructus Arctii, Radix Platycodonis, Periostracum Cicadae, Radix Bupleuri, Fructus Aurantii, Radix Glycyrrhizae.In the party, taking Radix Ophiopogonis, Radix Salviae Miltiorrhizae as principal agent, nourishing yin and promoting blood circulation, is aided with Radix Scrophulariae, Radix Paeoniae Rubra, Rhizoma Chuanxiong enhancing nourishing yin and activating blood effect.Be added with Fructus Arctii, Radix Platycodonis, Periostracum Cicadae sore-throat relieving.Through with Radix Bupleuri, Fructus Aurantii circulation of qi promoting with promoting blood.Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, plays YIN nourishing sore-throat relieving altogether, the effect of promoting flow of QI and blood, and aggregate efficiency reaches 85.11% (Peng Shunlin, etc., the routine observation of curative effect of nourishing yin and promoting blood circulation sore-throat relieving soup treatment chronic pharyngitis 47, the Gansu traditional Chinese medical science,, 11 6 phases of volume in 1998).
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition for the treatment of chronic pharyngitis.Another object of the present invention is to provide preparation method and the purposes of this pharmaceutical composition.
The invention provides a kind of pharmaceutical composition for the treatment of chronic pharyngitis, its crude drug comprises following weight proportion:
12～18 parts of Fructus Chebulaes, 3～9 parts of Fructus Phyllanthis, Fructus Mume 12-18 part, 3～9 parts of FLOS MUME, 7～13 parts, Radix Glycyrrhizae, 9～15 parts of Radix Platycodoniss, 17～23 parts of Radix Scrophulariaes, 5～11 parts of Flos Chrysanthemis, 12～18 parts of Fructus Momordicaes, 5～11 parts of Semen Sterculiae Lychnophoraes.
Further, its crude drug comprises the flavour of a drug of following weight proportion:
15 parts of Fructus Chebulaes, 6 parts of Fructus Phyllanthis, 15 parts of Fructus Mumes, 6 parts of FLOS MUME, 10 parts, Radix Glycyrrhizae, 12 parts of Radix Platycodoniss, 20 parts of Radix Scrophulariaes, 8 parts of Flos Chrysanthemis, 15 parts of Fructus Momordicaes, 8 parts of Semen Sterculiae Lychnophoraes.
Further, described crude drug weight proportion is as follows:
12～18 parts of Fructus Chebulaes, 3～9 parts of Fructus Phyllanthis, Fructus Mume 12-18 part, 3～9 parts of FLOS MUME, 7～13 parts, Radix Glycyrrhizae, 9～15 parts of Radix Platycodoniss, 17～23 parts of Radix Scrophulariaes, 5～11 parts of Flos Chrysanthemis, 12～18 parts of Fructus Momordicaes, 5～11 parts of Semen Sterculiae Lychnophoraes.
Preferably, described crude drug weight proportion is as follows:
15 parts of Fructus Chebulaes, 6 parts of Fructus Phyllanthis, 15 parts of Fructus Mumes, 6 parts of FLOS MUME, 10 parts, Radix Glycyrrhizae, 12 parts of Radix Platycodoniss, 20 parts of Radix Scrophulariaes, 8 parts of Flos Chrysanthemis, 15 parts of Fructus Momordicaes, 8 parts of Semen Sterculiae Lychnophoraes.
Wherein, it be by the medicated powder of crude drug, water extract or/and ethanol extraction is active component, add the dosage form that pharmaceutically conventional adjuvant or complementary composition are prepared from.
The form of medication such as water extract or be used as medicine with medicated powder, is all Chinese medicine tradition occupation modes, after water extraction, because the soluble end of water is wide, can, by most of effective ingredient stripping, medicine is more easily absorbed by the body, and onset is faster, such as decoction; Be used as medicine with former powder, the surface area of medicated powder is larger, also be conducive to effective ingredient absorption in vivo in medical material, but medical material un-extracted, effective ingredient still needs stripping in vivo to absorb again, and the relative water extract of its onset is slower, but has also weakened the toxicity that in medical material, harmful components cause human body simultaneously, be suitable for long-term taking, as former powder is prepared into the form of medication such as pill.At present in pharmacy procedure, ethanol extracts medicine as solvent, also be one of the most common extracting mode, ethanol is semi-polarity solvent, solubility property circle is between polarity and non-polar solven, can dissolve water miscible some composition, also can dissolve some compositions that non-polar solven dissolves, conventionally replace decocting with ethanol extraction, thereby avoid the stripping of a large amount of invalid components, improve concentration and the extraction efficiency of effective ingredient, but the price of ethanol is expensive compared with water, in the large production of modern pharmaceutical industry, in order to save production cost, conventionally still taking decocting as main.In the situation that known compositions water extraction liquid of the present invention has physiologically active, for adapt to various production and use time demand, optionally water extraction, former powder, alcohol extraction or their combined method are prepared concrete dosage form.
Pharmaceutically acceptable adjuvant of the present invention includes but are not limited to filler (diluent), lubricant (fluidizer or antitack agent), dispersant, wetting agent, binding agent, regulator, solubilizing agent, antioxidant, antibacterial, emulsifying agent, disintegrating agent etc.Binding agent comprises syrup, arabic gum, gelatin, sorbitol, tragacanth, cellulose and derivant thereof (as microcrystalline Cellulose, sodium carboxymethyl cellulose, ethyl cellulose or hydroxypropyl methylcellulose etc.), gelatine size, syrup, starch slurry or polyvinylpyrrolidone etc.; Filler comprises lactose, Icing Sugar, dextrin, starch and derivant thereof, cellulose and derivant thereof, inorganic calcium salt (as calcium sulfate, calcium phosphate, calcium hydrogen phosphate, precipitated calcium carbonate etc.), sorbitol or glycine etc.; Lubricant comprises micropowder silica gel, magnesium stearate, Pulvis Talci, aluminium hydroxide, boric acid, hydrogenated vegetable oil, Polyethylene Glycol etc.; Disintegrating agent comprises starch and derivant (as carboxymethyl starch sodium, Explotab, pregelatinized Starch, modified starch, hydroxypropyl starch, corn starch etc.), polyvinylpyrrolidone or microcrystalline Cellulose etc.; Wetting agent comprises sodium lauryl sulphate, water or alcohol etc.; Antioxidant packages is containing sodium sulfite, sodium sulfite, sodium pyrosulfite, dibutyl benzoic acid etc.; Antibacterial comprises 0.5% phenol, 0.3% cresol, 0.5% chlorobutanol etc.; Regulator comprises hydrochloric acid, citric acid, potassium hydroxide (sodium), sodium citrate and buffer agent (comprising phosphoric acid dioxy sodium and sodium hydrogen phosphate) etc.; Emulsifier package containing Tween-80, do not have that sour Pyrusussuriensis is smooth, pluronic gram F-68, lecithin, fabaceous lecithin etc.; Solubilizing agent comprises tween 80, bile, glycerol etc.
Described pharmaceutically acceptable complementary composition, it has certain physiologically active, but adding of this composition can not change above-mentioned food, health product or pharmaceutical composition in disease treatment or to the leading position in human body physiological function improvement process, and only effect is assisted in performance, these auxiliary effects are only the utilizations to this composition known activity, are the usual supplementary modes of field of medicaments or healthcare field.
Wherein, described dosage form is through gastrointestinal administration dosage form.For example, medicinal tea, tablet, powder, pill, capsule, granule or oral liquid.
The present invention also provides the preparation method of aforementioned pharmaceutical compositions, and it comprises following operating procedure:
(1) by proportioning weighting raw materials;
(2) medicated powder of crude drug, water extract, or/and ethanol extraction is active component, add that pharmaceutically conventional adjuvant or complementary composition are prepared into dosage form.
The present invention also provides the purposes of aforementioned pharmaceutical compositions in the medicine of preparation treatment chronic pharyngitis.
Further, described medicine is the medicine for the treatment of chronic simple pharyngitis or chronic hypertrophic pharyngitis.
Fructus Phyllanthi relieving sore-throat by clearing away heat in side, nourishing the lung to arrest cough, is our monarch drug.Radix Scrophulariae, Semen Sterculiae Lychnophorae, Fructus Mume sore-throat relieving promote the production of body fluid and are ministerial drug, the circulation of qi promoting of FLOS MUME fragrance, dissipating phlegm and resolving masses; Fructus Chebulae's sore-throat relieving of astringing the lung; Flos Chrysanthemi heat clearing away; Radix Platycodonis reduces phlegm; Fructus Momordicae smooth throat to stop cough is controlled expectorant, heat, void that pharyngitis causes, is coughed all diseases with assistant, and is adjuvant drug.In the Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription side of being, make medicine.
Pharmaceutical composition of the present invention can effectively be treated chronic pharyngitis, to pharyngeal sense of discomfort, foreign body sensation, gargalesthesia, burning sensation, dry sensation or excitement due to pharyngitis, hypodynia, cough, follow nauseating, pharyngeal mucosa thickens, have the symptoms such as sticky or glutinous purulent secretion to have the effects such as elimination or alleviation, and treatment total effective rate is high, for clinical application provides new selection.
Obviously,, according to foregoing of the present invention, according to ordinary skill knowledge and the customary means of this area, not departing under the above-mentioned basic fundamental thought of the present invention prerequisite, can also make amendment, replacement or the change of other various ways.
The detailed description of the invention of form by the following examples, is described in further detail foregoing of the present invention again.But this should be interpreted as to the scope of the above-mentioned theme of the present invention only limits to following example.All technology realizing based on foregoing of the present invention all belong to scope of the present invention.
Detailed description of the invention
The preparation method of embodiment 1 pharmaceutical composition of the present invention
Fructus Chebulae 15g, Fructus Phyllanthi 6g, Fructus Mume 15g, FLOS MUME 6g, Radix Glycyrrhizae 10g, Radix Platycodonis 12g, Radix Scrophulariae 20g, Flos Chrysanthemi 8g, Fructus Momordicae 15g, Semen Sterculiae Lychnophorae 8g.
Get above-mentioned raw materials medicine, by each component crushed after being dried, sieve is got the medicated powder of certain particle size, makes bag tea agent or powder, every packed amount 2g after mix homogeneously.
The preparation method of embodiment 2 pharmaceutical compositions of the present invention
Fructus Chebulae 18g, Fructus Phyllanthi 3g, Fructus Mume 12g, FLOS MUME 3g, Radix Glycyrrhizae 7g, Radix Platycodonis 9g, Radix Scrophulariae 17g, Flos Chrysanthemi 5g, Fructus Momordicae 12g, Semen Sterculiae Lychnophorae 5g.Get above-mentioned raw materials medicine, decoct with water 3 times, decoct 30min at every turn, merge decocting liquid, obtain decoction.
The preparation method of embodiment 3 pharmaceutical compositions of the present invention
Fructus Chebulae 12g, Fructus Phyllanthi 9g, Fructus Mume 18g, FLOS MUME 9g, Radix Glycyrrhizae 13g, Radix Platycodonis 15g, Radix Scrophulariae 23g, Flos Chrysanthemi 11g, Fructus Momordicae 18g, Semen Sterculiae Lychnophorae 11g.Get above-mentioned raw materials medicine, decoct with water 3 times, decoct 30min at every turn, merge decocting liquid, concentrated, leave standstill, get supernatant, reconcentration, adds appropriate amount of auxiliary materials, prepares unguentum, oral liquid or syrup.
The preparation method of embodiment 4 pharmaceutical compositions of the present invention
Fructus Chebulae 13g, Fructus Phyllanthi 7g, Fructus Mume 16g, FLOS MUME 5g, Radix Glycyrrhizae 9g, Radix Platycodonis 11g, Radix Scrophulariae 18g, Flos Chrysanthemi 6g, Fructus Momordicae 17g, Semen Sterculiae Lychnophorae 10g.First use 75% alcohol reflux 2 times, collect alcohol extract, medicinal residues decoct with water 2 times again, merge decocting liquid, and alcohol extract is reclaimed after ethanol, mix with decocting liquid, concentrated, add appropriate amount of auxiliary materials to prepare granule, tablet or capsule.
The preparation method of embodiment 5 pharmaceutical compositions of the present invention
Fructus Chebulae 15g, Fructus Phyllanthi 6g, Fructus Mume 15g, FLOS MUME 6g, Radix Glycyrrhizae 10g, Radix Platycodonis 12g, Radix Scrophulariae 20g, Flos Chrysanthemi 8g, Fructus Momordicae 15g, Semen Sterculiae Lychnophorae 8g.Decoct with water 3 times, merge decocting liquid, concentrated, add appropriate amount of auxiliary materials to prepare buccal tablet.
Illustrate beneficial effect of the present invention by test example below.
Test example 1 clinical effectiveness
Chronic pharyngitis is accepted standard for medical treatment: accepting for medical treatment through diagnosis is that chronic simple pharyngitis or chronic hypertrophic pharyngitis patient have 378 examples.
The symptom that patient occurs comprises pharyngeal sense of discomfort, foreign body sensation, gargalesthesia, burning sensation, dry sensation or excitement, also may be with hypodynia, and there is cough, follow nauseatingly, the pharyngeal mucosa of some patients were thickens, and has sticky or glutinous purulent secretion.
Therapeutic Method: the bagged steeping drug that uses the embodiment of the present invention 1 to prepare, take every day 1 time, the medicinal bag infusion of 2g crude drug loading amount is taken after mixing it with hot water, be 5-11 days the course for the treatment of.
Therapeutic outcome (following table is classified with same symptoms):
Table 1
Table 2
Table 3
Table 4
From above-mentioned experimental result, pharmaceutical composition of the present invention can effectively be treated chronic pharyngitis, to pharyngeal sense of discomfort, foreign body sensation, gargalesthesia, burning sensation, dry sensation or excitement due to pharyngitis, hypodynia, cough, follow nauseating, pharyngeal mucosa thickens, and have the symptoms such as sticky or glutinous purulent secretion to have the effects such as elimination or alleviation, and treatment total effective rate is high.
Discuss:
The present invention, at the research initial stage, in order to obtain efficacy stability, the better prescription of therapeutic effect, investigates compatibility flavour of a drug, through relatively, finally determines that the present invention's prescription is for the best side, and concrete comparing data is as follows:
(1) contrast groups 1: 15 parts of Fructus Chebulaes, 6 parts of Fructus Phyllanthis, 6 parts of FLOS MUME, 10 parts, Radix Glycyrrhizae, 12 parts of Radix Platycodoniss, 20 parts of Radix Scrophulariaes, 8 parts of Flos Chrysanthemis, 15 parts of Fructus Momordicaes.Prepare bag tea agent according to embodiment 1 method, every packed amount 2g.
Contrast groups 1 and bag tea agent prepared by embodiment 1 are treated respectively to 30 people, and it the results are shown in following table:
The impact on all kinds of pharyngeal senses of discomfort of patient of table 5 chronic pharyngitis bagged steeping drug and contrast groups
(2) contrast groups 2: 15 parts of Fructus Chebulaes, 6 parts of Fructus Phyllanthis, 15 parts of Fructus Mumes, 6 parts of FLOS MUME, 10 parts, Radix Glycyrrhizae, 12 parts of Radix Platycodoniss, 15 parts of Fructus Momordicaes, 8 parts of Semen Sterculiae Lychnophoraes.Prepare bag tea agent according to embodiment 1 method, every packed amount 2g.
Contrast groups 2 and bag tea agent prepared by embodiment 1 are treated respectively to 30 people, and it the results are shown in following table:
The impact on the pharyngeal hypodynia symptom of patient of table 6 chronic pharyngitis bagged steeping drug and contrast groups
(3) contrast groups 3: 6 parts of Fructus Phyllanthis, 15 parts of Fructus Mumes, 6 parts of FLOS MUME, 10 parts, Radix Glycyrrhizae, 12 parts of Radix Platycodoniss, 20 parts of Radix Scrophulariaes, 8 parts of Flos Chrysanthemis, 8 parts of Semen Sterculiae Lychnophoraes.Prepare bag tea agent according to embodiment 1 method, every packed amount 2g.
Contrast groups 3 and bag tea agent prepared by embodiment 1 are treated respectively to 30 people, and it the results are shown in following table:
Table 7 chronic pharyngitis bagged steeping drug and contrast groups are on all kinds of pharyngeal coughs of patient, nauseating impact
(4) contrast groups 4: 15 parts of Fructus Chebulaes, 6 parts of Fructus Phyllanthis, 15 parts of Fructus Mumes, 10 parts, Radix Glycyrrhizae, 20 parts of Radix Scrophulariaes, 8 parts of Flos Chrysanthemis, 15 parts of Fructus Momordicaes, 8 parts of Semen Sterculiae Lychnophoraes.Prepare bag tea agent according to embodiment 1 method, every packed amount 2g.
Contrast groups 4 and bag tea agent prepared by embodiment 1 are treated respectively to 30 people, and it the results are shown in following table:
The impact on patient's pharyngeal mucosa pathological changes and secretions of table 8 chronic pharyngitis bagged steeping drug and contrast groups
From the above results, although the prescription flavour of a drug of contrast groups 1～4 are comparatively similar to the present invention, but, under identical dosage, bag tea agent of the present invention is obviously better than contrast groups 1～4 to the therapeutical effect of pharyngitis, this just shows, the flavour of a drug compatibility of pharmaceutical composition of the present invention is precise and appropriate, and each flavour of a drug are indispensable.
Claims (9)
1. a pharmaceutical composition for the treatment of chronic pharyngitis, is characterized in that: its crude drug comprises the flavour of a drug of following weight proportion:
12～18 parts of Fructus Chebulaes, 3～9 parts of Fructus Phyllanthis, Fructus Mume 12-18 part, 3～9 parts of FLOS MUME, 7～13 parts, Radix Glycyrrhizae, 9～15 parts of Radix Platycodoniss, 17～23 parts of Radix Scrophulariaes, 5～11 parts of Flos Chrysanthemis, 12～18 parts of Fructus Momordicaes, 5～11 parts of Semen Sterculiae Lychnophoraes.
2. pharmaceutical composition according to claim 1, is characterized in that: its crude drug comprises the flavour of a drug of following weight proportion:
15 parts of Fructus Chebulaes, 6 parts of Fructus Phyllanthis, 15 parts of Fructus Mumes, 6 parts of FLOS MUME, 10 parts, Radix Glycyrrhizae, 12 parts of Radix Platycodoniss, 20 parts of Radix Scrophulariaes, 8 parts of Flos Chrysanthemis, 15 parts of Fructus Momordicaes, 8 parts of Semen Sterculiae Lychnophoraes.
3. pharmaceutical composition according to claim 1, is characterized in that: described crude drug is made up of the flavour of a drug of following weight proportion:
12～18 parts of Fructus Chebulaes, 3～9 parts of Fructus Phyllanthis, Fructus Mume 12-18 part, 3～9 parts of FLOS MUME, 7～13 parts, Radix Glycyrrhizae, 9～15 parts of Radix Platycodoniss, 17～23 parts of Radix Scrophulariaes, 5～11 parts of Flos Chrysanthemis, 12～18 parts of Fructus Momordicaes, 5～11 parts of Semen Sterculiae Lychnophoraes.
4. pharmaceutical composition according to claim 3, is characterized in that: described crude drug is made up of the flavour of a drug of following weight proportion:
15 parts of Fructus Chebulaes, 6 parts of Fructus Phyllanthis, 15 parts of Fructus Mumes, 6 parts of FLOS MUME, 10 parts, Radix Glycyrrhizae, 12 parts of Radix Platycodoniss, 20 parts of Radix Scrophulariaes, 8 parts of Flos Chrysanthemis, 15 parts of Fructus Momordicaes, 8 parts of Semen Sterculiae Lychnophoraes.
5. according to the pharmaceutical composition described in claim 1～4 any one, it is characterized in that: it be by the medicated powder of crude drug, water extract or/and ethanol extraction is active component, add the dosage form that pharmaceutically conventional adjuvant or complementary composition are prepared from.
6. pharmaceutical composition according to claim 5, is characterized in that: described dosage form is through gastrointestinal absorption dosage form.
7. the preparation method of pharmaceutical composition described in claim 1～6 any one, is characterized in that: it comprises following operating procedure:
(1) by proportioning weighting raw materials;
(2) medicated powder of crude drug, water extract, or/and ethanol extraction is active component, add that pharmaceutically conventional adjuvant or complementary composition are prepared into dosage form.
8. the purposes of pharmaceutical composition in the medicine of preparation treatment chronic pharyngitis described in claim 1～6 any one.
9. purposes according to claim 8, is characterized in that: described medicine is the medicine for the treatment of chronic simple pharyngitis or chronic hypertrophic pharyngitis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410305488.9A CN104042767B (en) | 2014-06-30 | 2014-06-30 | A kind of pharmaceutical composition for the treatment of chronic pharyngitis and its production and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410305488.9A CN104042767B (en) | 2014-06-30 | 2014-06-30 | A kind of pharmaceutical composition for the treatment of chronic pharyngitis and its production and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104042767A true CN104042767A (en) | 2014-09-17 |
| CN104042767B CN104042767B (en) | 2016-04-13 |
Family
ID=51496490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410305488.9A Active CN104042767B (en) | 2014-06-30 | 2014-06-30 | A kind of pharmaceutical composition for the treatment of chronic pharyngitis and its production and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104042767B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491372A (en) * | 2014-11-27 | 2015-04-08 | 恩施硒都科技园有限公司 | Radix scrophulariae buccal tablet |
| CN106418530A (en) * | 2016-08-25 | 2017-02-22 | 苏州神元生物科技股份有限公司 | Health care product capable of clearing heat from throat |
| CN110548077A (en) * | 2019-09-04 | 2019-12-10 | 成都市康飞药业有限公司 | Pharmaceutical composition for treating chronic pharyngitis and preparation method and application thereof |
| CN117731737A (en) * | 2024-02-19 | 2024-03-22 | 云南红青夫生物科技股份有限公司 | Throat-clearing and-wetting lozenge |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1486731A (en) * | 2003-07-30 | 2004-04-07 | 上海玉森新药开发有限公司 | Throat benefiting detoxication prepn |
-
2014
- 2014-06-30 CN CN201410305488.9A patent/CN104042767B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1486731A (en) * | 2003-07-30 | 2004-04-07 | 上海玉森新药开发有限公司 | Throat benefiting detoxication prepn |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491372A (en) * | 2014-11-27 | 2015-04-08 | 恩施硒都科技园有限公司 | Radix scrophulariae buccal tablet |
| CN104491372B (en) * | 2014-11-27 | 2016-02-03 | 恩施硒都科技园有限公司 | A kind of Radix Scrophulariae buccal tablet |
| CN106418530A (en) * | 2016-08-25 | 2017-02-22 | 苏州神元生物科技股份有限公司 | Health care product capable of clearing heat from throat |
| CN110548077A (en) * | 2019-09-04 | 2019-12-10 | 成都市康飞药业有限公司 | Pharmaceutical composition for treating chronic pharyngitis and preparation method and application thereof |
| CN110548077B (en) * | 2019-09-04 | 2021-08-20 | 成都市康飞药业有限公司 | Pharmaceutical composition for treating chronic pharyngitis and preparation method and application thereof |
| CN117731737A (en) * | 2024-02-19 | 2024-03-22 | 云南红青夫生物科技股份有限公司 | Throat-clearing and-wetting lozenge |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104042767B (en) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102743737A (en) | Chinese medicinal preparation for effectively treating tracheitis | |
| WO2021208335A1 (en) | Traditional chinese medicine composition capable of removing toxins, dispelling dampness, and disinhibiting throat, and application thereof | |
| CN104042767B (en) | A kind of pharmaceutical composition for the treatment of chronic pharyngitis and its production and use | |
| WO2021179505A1 (en) | Forsythia suspensa and astragalus membranaceus compound preparation, preparation method therefor and application thereof | |
| CN111388582A (en) | Traditional Chinese medicine composition for treating novel coronavirus pneumonia and application of preparation thereof | |
| CN103977314A (en) | Medicinal composition for treating respiratory diseases as well as preparation method and application of medicinal composition | |
| CN103656015A (en) | Pure traditional Chinese medicine preparation for treating childhood asthma and preparation method thereof | |
| CN102091195B (en) | Medicament for treating snore and sleep apnea syndrome | |
| CN111840456A (en) | Chinese medicinal composition for treating respiratory system diseases | |
| CN103211990A (en) | Chinese medicinal composition for treating oral ulcer | |
| CN105055841A (en) | Medicine for treating chronic pharyngitis and preparing method thereof | |
| CN105250843A (en) | Medicament for treating cough due to wind-heat evil | |
| CN115486488A (en) | Tea drink composition for common food and application thereof | |
| CN101380411A (en) | Traditional Chinese medicine preparation for relieving cough and reducing sputum | |
| CN103446445A (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency-type chronic bronchitis and preparation method thereof | |
| CN106215148A (en) | A kind of Chinese medicine composition treating bronchial asthma and preparation method thereof | |
| CN104758884A (en) | Traditional Chinese medicine composition for treating asthma | |
| CN103356798A (en) | Application of chronic-gastritis-treating traditional Chinese medicine in preparing medicine used for preventing gastric ulcer | |
| CN114917287B (en) | Traditional Chinese medicine composition for treating allergic asthma, preparation method and application thereof | |
| CN105878996A (en) | Traditional Chinese medicine composition for treating emphysema | |
| CN101732634A (en) | Chinese medicament for treating silicosis | |
| CN100333777C (en) | Medicine for improving enterogastric function after radiation chemiotherapy | |
| CN106880722A (en) | It is a kind of to treat compound traditional Chinese medicine composite of rhinitis and preparation method thereof | |
| CN105055829A (en) | Medicine used for treating chronic laryngitis | |
| CN104888112A (en) | Medicine for treating recurrent oral ulceration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |